Abstract: OBJECTIVE To explore the clinical efficacy of vancomycin in treatment of neonates with coagulase-negative Staphylococcus infections and analyze the renal toxicity so as to provide guidance for clinical treatment of the neonates with infections. METHODS A total of 128 neonates with coagulase-negative Staphylococcus infections who were treated in the hospital from Mar 2013 to Mar 2016 were recruited as the study objects and divided into the observation group and the control group according to the use of antibiotics, with 64 cases in each group.The observation group was treated with vancomycin combined with broad-spectrum penicillins, while the control group was only treated with broad-spectrum penicillins.The renal function-related indexes of the children were examined before the treatment and after the drug discontinuation for 1 week.The clinical therapeutic effects and the renal toxicity were evaluated and compared between the two groups of children. RESULTS The total effective rate of treatment of the observation group was 98.4%, significantly higher than 89.1% of the control group(P＜0.05).In the observation group, the routine urine test was abnormal in 5 cases, with the incidence rate 7.8%; the urea nitrogen test was abnormal in 6 cases, with the incidence rate 9.3%; the creatinine test was abnormal in 4 cases, wit the incidence rate 6.2%; there were no significant differences between the observation group and the control group.The levels of urine protein, urine α1-microglobulin and urine NAG were respectively (0.053±0.017)g/L,(6.413±2.184)g/L and (9.481±3.951)g/L in the observation group after the treatment and were respectively (0.058±0.021)g/L, (6.621±3.244)g/L and (10.116±4.034)g/L in the control group, and there were no significant differences between the two groups. CONCLUSION Vancomycin can achieve remarkable effect on treatment of the neonates with coagulase-negative Staphylococcus infections and have less renal toxicity to the children, therefore, it is an effective way to choose reasonable dosage of vancomycin and appropriate treatment approach so as to control the coagulase-negative Staphylococcus infections in the neonates and improve the therapeutic effect.